Revance Therapeutics, Inc. 4
4 · Revance Therapeutics, Inc. · Filed Sep 2, 2014
Insider Transaction Report
Form 4
Bertolino Arthur Peter
EVP and Chief Medical Officer
Transactions
- Award
Common Stock
2014-09-02+39,375→ 39,375 total - Award
Stock Option (Right to buy)
2014-09-02+118,125→ 118,125 totalExercise: $22.97Exp: 2024-09-01→ Common Stock (118,125 underlying)
Footnotes (2)
- [F1]The restricted stock award shall vest over a period of four years with 25% vesting annually commencing on September 2, 2014.
- [F2]The shares subject to the stock option shall vest over a period of four years, with 25% of the underlying shares vesting on September 2, 2015 and 1/48 of the total number of underlying shares vesting each month over the remaining three years.